Fresenius Medical Care Credit Rating & NNN Cap Rate

Fresenius Medical Care operates outpatient dialysis clinics for people with kidney failure and also makes dialysis machines and supplies. For net lease investors, Fresenius is a major U.S. dialysis tenant: it treats around 37% of U.S. dialysis patients, according to its Form 20‑F for 2025, and DaVita is another large U.S. operator. Its parent company carries an investment grade rating.

Business Overview

Fresenius Medical Care reports three operating segments: Care Delivery, which runs dialysis clinics, Value-Based Care, and Care Enablement, which makes dialysis products. In the U.S. it treated 203,177 patients in 2,539 clinics at June 30, 2026. That clinic count was down 3% from a year earlier: the company reported U.S. clinic closures and “clinic footprint optimization” as part of a broad transformation, along with exits from markets it considers unsustainable and divestitures of non-core businesses.

In June 2025 the company launched its FME Reignite strategy. Its expanded FME25+ cost program targets €1.2 billion of cumulative sustainable savings by the end of 2027 (Form 6‑K for the quarter ended June 30, 2026). For landlords, the relevant point is that Fresenius is actively closing and consolidating clinics, so the strength of each location matters.

Credit Profile

Fresenius Medical Care AG is rated BBB- by S&P and Baa3 (Stable) by Moody’s, and our ratings database classifies it as investment grade. BBB‑ at S&P and Baa3 at Moody’s are the lowest investment grade ratings, so a one-notch downgrade from either of those levels would fall below investment grade. DaVita, another large U.S. dialysis operator, is rated BB; our database classifies it as not investment grade. Ratings come from our tenant ratings database, which records the source of each rating.

The rating belongs to the German parent. U.S. clinics are operated through subsidiaries, so the tenant named in a lease is often a U.S. subsidiary. Confirm the tenant entity and whether a parent company guarantees the lease before relying on the parent’s rating.

Source: S&P Global Ratings BBB-, as of May 23, 2024; Moody’s Baa3, Stable, as of June 30, 2026; Fitch Ratings BBB-, as of July 21, 2026. Ratings checked October 8, 2026.

Fresenius NNN Cap Rates

Live asking cap rates for Fresenius and other outpatient healthcare tenants:

Active listings InvestmentGrade.com tracks with an asking cap rate (stated in the listing, or computed from its stated income and price when no rate is stated), listings last observed October 12, 2026. Asking cap rates are not closed-sale cap rates. The middle half is the range from the 25th to the 75th percentile of listings. The 10-year Treasury yield is 5.24% as of October 1, 2026 (FRED series DGS10). Ratings are the agency ratings in our ratings database for the entity shown, which may be a parent company; the rating type (for example issuer, senior unsecured debt, long-term debt or revenue bond ratings) varies by company and is shown on each tenant page. A rating applies to a lease only if the rated entity signs or guarantees it, so confirm the tenant and any guarantor in the lease. n/a means no verified rating is on file. Not shown because fewer than 3 active listings with a published cap rate were observed: Us Renal Care, Quest Diagnostics, Labcorp.

A stronger parent rating does not by itself mean a lower asking cap rate for a given clinic. Dialysis clinic pricing also depends on the clinic’s patient volume, remaining lease term, rent level, the lease obligor and the building’s re-use potential. Fresenius listings InvestmentGrade.com currently tracks: 6.

What to Check in a Fresenius Lease

• Tenant and guarantor: which entity signs the lease and whether a parent company guarantees it.
• Term and rent increases: remaining term, renewal options and the rent schedule; terms vary by lease.
• Clinic performance: patient count or treatment volume where the seller can provide it, and how close the nearest competing clinics are.
• Closure risk: Fresenius has been closing and consolidating U.S. clinics; ask whether the location has been relocated, expanded or reduced.
• Building and re-use: dialysis clinics need water treatment and plumbing that other users may not; consider how the space would be re-leased.
• Reimbursement: Fresenius receives a substantial portion of its Care Delivery revenue from the U.S. Medicare program and other government sources (Form 20‑F for 2025), so payment policy changes affect the operator.

Pros and Cons

Sources: Fresenius Medical Care AG Form 20‑F for 2025 and Form 6‑K report for the quarter ended June 30, 2026.